Tissue Factor Immobilized Wound Dressing for Local Haemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound dressings fail to effectively promote rapid haemostasis while preventing undesirable systemic coagulation, as they often lead to unsafe clotting due to the leakage of active components like Tissue Factor into the bloodstream, posing a risk of uncontrolled thrombosis.
Innovation Solution
A system comprising Tissue Factor immobilized on a dressing material, where the Tissue Factor is permanently linked to prevent dissociation from the dressing, ensuring local clot formation without systemic exposure, thereby promoting safe and efficient haemostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tissue Factor is applied to a dressing material to promote haemostasis, then local clot formation is initiated, but the Tissue Factor may leak into the bloodstream causing systemic coagulation
Solution Approach 1:
The patent uses a dressing material as an intermediary carrier that binds Tissue Factor through immobilization techniques. This intermediary prevents direct contact between Tissue Factor and the bloodstream while still enabling local haemostatic activity at the wound site, thus resolving the contradiction between effective haemostasis and preventing systemic coagulation
Solution Approach 2:
The patent applies Tissue Factor locally to the dressing material at the wound site rather than systemically. The immobilized Tissue Factor remains confined to the local area where it is needed for haemostasis, preventing widespread systemic coagulation while maintaining effective local clot formation
2Object-affected harmful factors
If Tissue Factor is immobilized on a dressing material to prevent leakage, then safety is improved, but the complexity of the system increases
Solution Approach 1:
The patent modifies the physical and chemical parameters of the dressing material surface to enable Tissue Factor immobilization. By changing surface properties such as charge, hydrophobicity, or introducing specific binding groups, the dressing material can securely hold Tissue Factor without requiring complex structural modifications, thus reducing overall system complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system initiates rapid and sustained haemostasis at the site of injury while preventing undesirable systemic blood coagulation, ensuring safety and efficacy by maintaining Tissue Factor on the dressing material, thus reducing the risk of uncontrolled clotting.
Implementation Method 1
Coagulation (thrombogenesis) is the process by which blood form clots, and it is an important part of haemostasis
Implementation Method 2
The Tissue Factor-FVIIa complex assembles on a negatively charged membrane surface in a calcium dependent manner to form an enzyme complex, which proteolytically converts factor IX and X to factor IXa and Xa, respectively
Implementation Method 3
Once thrombin is generated, it cleaves fibrinogen releasing fibrinopeptides A and B—often referred to as FPA and FPB, respectively, and activates factor XIII to form a cross-linked fibrin clot
Implementation Method 4
the Tissue Factor is covalently bound to the dressing material, which may be a component of the dressing or integrated therein
Data Source
AI summary
The present invention relates to a safe and efficient system to improve haemostatic control by immobilization of Tissue Factor protein to a dressing material suitable for use as or in a wound dressing, bringing Tissue Factor in direct contact to the wound. The present invention aims at using immobilized Tissue Factor to generate a “thrombin burst”, a process by which thrombin, the most important constituent of the coagulation cascade is released very rapidly. There is no systemic release of the protein Tissue Factor into the vascular bed. The linked protein Tissue Factor can be used alone or in combination with other human proteins or components to optimise haemostasis.